Gly­copy­rro­late CAS 596-51-0

Iden­ti­fi­ca­tion

CAS Number

596-51-0

Name

Gly­copy­rro­late

Syn­onyms

α-cyclopentyl­­man­del­ic acid ester with 3-hydroxy-1,1-dimethylpyrrolidinium bro­mide 1-methyl-3-pyrrolidyl α-cyclopentyl­­man­de­late metho­bro­mide 1-methyl-3-pyrrolidyl α-phenyl-α-cyclopentyl­g­ly­­co­late metho­bro­mide 3-(2-phenyl-2-cyclopentylglycoloyloxy)-1,1-dimethylpyrrolidinium bro­mide 3-hydroxy-1,1-dimethylpyrrolidinium bro­mide α-cyclopentyl­­man­de­late AHR-504 Copy­rro­late Gas­tro­dyn NSC 250836 NSC 251251 NSC 251252 NVA-237 gly­copy­rro­ni­um bro­mide

Mol­e­c­u­lar Structure

SMILES

O=C(OC1CC[N+](C)(C)C1)C(O)(c2ccccc2)C3CCCC3

Std­InChI

InChI=1S/C19H28NO3/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3/q+1

Std­InChIKey

ANGKOCU­UWGHLCE-UHF­F­­FAOYSA-N

EINECS

209-887-0

Mol­e­c­u­lar Formula

C19H28NO3​.Br

Mol­e­c­u­lar Weight

398.34

MDL Number

MFCD00072137

Prop­er­ties

Appear­ance

Off-white to white crys­talline pow­der

Sol­u­bil­i­ty

H2O : ≥24 mg/​mL

Melt­ing Point

193-198 °C

Safe­ty Data

Sym­bol

GHS07

Sig­nal Word

Warn­ing

Haz­ard Statements

H315-H319-H335

Pre­cau­tion­ary Statements

P261-P305 + P351 + P338

Haz­ard Codes (Europe)

Xi

Risk State­ments (Europe)

36/37/38

Safe­ty State­ments (Europe)

26

WGK Germany

3 

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our Gly­copy­rro­late CAS 596-51-0

Stan­dard

USP

Assay

98.0%-100.5%

Ordi­nary Impurities

Sin­gle : 0.5% max Total : 2.0% max

Relat­ed Compounds

Sin­gle : 0.1% max Total : 0.5% max

Resid­ual Solvents

Methyl Alco­hol : 3000ppm max Iso­propyl ether : 5000ppm max 2-Butanone : 3000ppm max n-Hep­­­tane : 5000ppm max Par­ti­cle Size : D90:≤80µm

Oth­er Doc­c­u­ments Avaiable

DMF

Iden­ti­fi­ca­tion Method

IR, HPLC

Known Appli­ca­tion

In anes­the­sia, gly­copy­rro­late injec­tion can be used as a pre­op­er­a­tive med­ica­tion in order to reduce salivary,tracheobronchial, and pha­ryn­geal secre­tions, as well as decreas­ing the acid­i­ty of gas­tric secre­tion. It is also used in con­junc­tion with neostig­mine, a neu­ro­mus­cu­lar block­ing rever­sal agent, to pre­vent neostigmine’s mus­carinic effects such as brady­car­dia. It is also used to reduce exces­sive sali­va (sial­or­rhea). It decreas­es acid secre­tion in the stom­ach and so may be used for treat­ing stom­ach ulcers, in com­bi­na­tion with oth­er med­ica­tions. Use in treat­ing asth­ma and COPD has been described. It has been used top­i­cal­ly and oral­ly to treat hyper­hidro­sis.

Pro­duc­tiv­i­ty

kg scale

Stor­age

2-8°C

Gen­er­al View of Documents

Wat­­son-Int Link

http://​wat​son​-int​.com/​G​l​y​c​o​p​y​r​r​o​l​a​t​e​_​C​A​S​_​5​9​6​-​5​1​-​0​.​h​tml